The GLP is committed to full transparency. Download and review our 2019 Annual Report

Bayer to appeal $2 billion glyphosate-cancer verdict with EPA Roundup assessment excluded from trial

| | May 16, 2019

Bayer plans to make the EPA’s safety endorsement of a chemical in Roundup central to its case as the company fights claims its weedkiller causes cancer.

In recent months, Bayer has been handed three jury verdicts ordering the company to pay more than $2 billion in damages to plaintiffs who believe exposure to Roundup caused their non-Hodgkin lymphoma ….

…. In April, the EPA released a draft risk assessment stating glyphosate is not a carcinogen …. a conclusion the agency has consistently made as it periodically reviews the herbicide. Attorneys for Bayer tried to introduce that evidence during the third trial …. but were rebuffed by the judge.

Related article:  Chemical companies: Reform WHO's 'rogue' IARC cancer-designating agency

Defense attorneys plan to make that judge’s ruling a key part of their attempt to overturn the third jury verdict during appeal

Read full, original article: Bayer to lean on EPA review of glyphosate in court battles (Behind Paywall)

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend